The Evolving Landscape of Peptide Compounding
Home Study Webinar
$20 Activity Fee
Topic Designator: 03 – Law | Credit: 1.25 contact hours Available through August 27, 2029
As federal regulatory activity surrounding peptide compounding continues to evolve, regulators face increasing complexity in oversight and enforcement. This webinar will examine the current regulatory framework governing peptide compounding, including federal activities related to the reclassification of peptides. Attendees will gain a clearer understanding of how these developments may impact compounding oversight.
This home study webinar is a recording of the live activity that was held on October 8, 2026.
Presenters
Kathleen Anderson, PharmD
Principal and Co-Founder, Compounding Strategy Advisors, LLC
Kathleen Anderson, PharmD, is a senior regulatory leader with more than 35 years of experience at the US Food and Drug Administration, specializing in compliance, enforcement, and complex prescription drug oversight. Anderson’s expertise extends across prescription drug labeling, marketed unapproved drugs, repackaging, API importation, and broader regulatory compliance strategy. She is widely recognized for her ability to translate complex regulatory requirements into practical, scalable programs that strengthen public health protections while maintaining workable paths for industry. Anderson received her bachelor of science degree in pharmacy from Duquesne University and her doctorate of pharmacy from the University of Arkansas.
Ilisa Bernstein, PharmD, JD, FAPhA
Principal and Co-Founder, Compounding Strategy Advisors, LLC
President, Bernstein Rx Solutions, LLC
Ilisa Bernstein, PharmD, JD, FAPhA, is a nationally recognized leader in drug and pharmacy regulatory strategy, policy, and compliance. Driven by a steadfast focus on drug quality and patient safety, she brings over 35 years of experience across government, nonprofit, and private sectors, including some of the most senior regulatory and professional roles in the pharmacy profession. Through Compounding Strategy Advisors, Bernstein applies decades of experience developing and implementing federal compounding policy to help stakeholders translate regulatory requirements into practical, actionable operational approaches. Through Bernstein Rx Solutions, she advises on drug and pharmacy regulatory policy and strategy, including drug supply chain security, distribution, pharmacy practice, and government affairs. Bernstein received her doctorate of pharmacy from the University of Michigan and her juris doctor degree from American University Washington.
Frances Gail Bormel, RPh, JD
Principal and Co-Founder, Compounding Strategy Advisors, LLC
Frances Gail Bormel, RPh, JD, is a nationally recognized leader in FDA compounding compliance and drug quality, with more than 30 years of experience across federal and state government, private legal practice, and regulated industry. She also has a proven record of building and leading high-performing organizations, shaping federal policy, directing major enforcement programs, and advising top government leadership. In addition, she has deep expertise in compounding, issues related to unapproved drugs, over-the-counter and import/export regulation, and federal and state pharmacy law. Bormel received her bachelor of science degree in pharmacy with high honors from the University of Maryland and her juris doctor degree with honors from The George Washington University.
